VRCA

Verrica has transitioned from a pure clinical-stage story to an early commercial one: FY2025 revenue jumped +370% to $35.6M in the second full year of the YCANTH (VP-102) molluscum launch, and the loss narrowed dramatically — net income improved from -$76.6M in FY2024 to -$17.9M, operating margin from deeply negative to -34.2%. The balance sheet carries no debt (long-term and current debt both $0), liabilities/equity of just 0.90x, and $30.1M of cash. On a $105M market cap that is a P/S of 3.0 — not demanding for a company still compounding revenue off a small base with a 40-rep (soon 50) specialty sales force and a newly launched YCANTH-Rx pharmacy to smooth reimbursement friction.

The problem is that the P&L improvement has not stopped the cash bleed. Operating cash flow was -$17.6M for FY2025 while cash fell 34.9% to $30.1M — roughly a 1.5–2 year runway before financing is required, and management itself flags in the MD&A that it 'may also pursue non-dilutive strategic partnerships to help fund' the Phase 3 program. With 17.2M shares (post an 81.3% reduction, i.e. a reverse split) and a -$325M accumulated deficit, the most likely funding path is dilutive, which caps near-term upside even if the commercial ramp continues. The MD&A also loads the story with capital-hungry ambitions: two Phase 3 BCC studies for VP-315, a global Phase 3 common-warts program with partner Torii (first patient dosed Dec 2025), and a European molluscum submission.